Shaw Patterns of Resistance in ALK Positive NSCLC

(6:2)

How do ALK-inhibitors work in ALK-positive lung cancer?

(2:50)

Case Study: Progression on ALK Inhibitors in NSCLC

(6:4)

Updates and unmet needs in ALK-mutated lung cancer

(1:25)

Choosing the best ALK inhibitor for lung cancer

(1:24)

What is treatment like for ALK-positive lung cancer?

(2:12)

Dr. Johung on Prognosis of Patients With ALK-Rearranged NSCLC and Brain Metastases

(59)

Dr. Shaw on Sequencing Strategies in ALK-Positive NSCLC

(1:57)

NSCLC: How to Handle ALK Resistance

(13:18)

ALK Inhibitor Sequencing in NSCLC

(6:27)

What is an ALK rearrangement in lung cancer?

(1:33)

Highlights on adjuvant alectinib in early ALK positive NSCLC: The ALINA study

(2:51)

What targeted therapies are used for people with the ALK mutation?

(1:5)

Case Presentation: ALK-Rearranged Metastatic NSCLC

(2:49)

ALK-Positive NSCLC

(8:51)

NAUTIKA1: safety and tolerability of neoadjuvant alectinib in ALK-positive NSCLC

(56)

ALK Positive Lung Cancer in 2023 and Beyond: Thinking Outside the Box with Dr. Alice Shaw

(42:31)

Second-Line Treatment for ALK-Positive NSCLC

(8:24)

Alectinib in ALK-Mutated NSCLC

(3:59)